Immunotherapy represents a significant advancement in prostate cancer treatment. However, resistance mechanisms pose major challenges. Customizing treatments to modify the tumor environment and improve immune recognition offers promise for better outcomes. Early detection and treatment are crucial for reducing tumor variability and enhancing therapeutic success. An in depth understanding of how tumors respond to immunotherapy will aid in developing new treatment strategies. CAR T-cell therapy holds potential for prostate cancer, but it is still in early development, and ongoing research is vital to overcoming current obstacles and improving patient outcomes.